The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | DART: ctDNA MRD as a prognostic biomarker in unresectable stage III NSCLC
Aslaug Helland, MD, PhD, University of Oslo, Oslo, Norway, discusses the DART trial (NCT04392505), evaluating circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy followed by durvalumab. Detectable ctDNA during the early post-treatment phase correlated with poorer progression-free and overall survival, supporting its potential role in identifying high-risk patients who may benefit from intensified or personalized treatment approaches. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is an investigator-initiated clinical trial. It’s called the DART trial and it’s for patients with locally advanced non-small cell lung cancer, non-operable. These patients are treated with both chemotherapy and radiotherapy and then thereafter they receive Durvalumab, which is immunotherapy. Some patients benefit but not all and we really need to understand more about why some respond well and why some patients do not...
This is an investigator-initiated clinical trial. It’s called the DART trial and it’s for patients with locally advanced non-small cell lung cancer, non-operable. These patients are treated with both chemotherapy and radiotherapy and then thereafter they receive Durvalumab, which is immunotherapy. Some patients benefit but not all and we really need to understand more about why some respond well and why some patients do not. It’s a curatively intended treatment, however the prognosis isn’t really very good. So in this study we did blood sampling at regular time points to see if we could use those blood samples to detect progression earlier and we did the analysis now on 20 patients so it’s preliminary data on a small subset of the patients but it seems that if we detect ctDNA in blood samples during the first four months of durvalumab, it’s indicating a worse prognosis and a higher risk of death.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding – AstraZeneca (Inst); Bristol Myers Squibb (Inst); GlaxoSmithKline (Inst); Illumina (Inst); InCyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Ultimovacs (Inst)
